JAK Inhibitor denied as duplicate or overlapping therapy by Cigna?

Cigna's specific coverage criteria for jak inhibitor are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denies a JAK Inhibitor as Duplicate Therapy

Cigna may deny a JAK inhibitor (Janus kinase inhibitor) on the grounds of duplicate therapy when the patient is already taking — or was recently taking — another medication from the same class, or when the plan's system flags it alongside a concurrent biologic as overlapping mechanism. The specific clinical context matters: the JAK inhibitor class is used across multiple conditions (rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, atopic dermatitis, and others), and the duplicate-therapy rationale differs depending on which two agents are being compared. The appeal should clarify the precise clinical situation — whether this is a class switch, a combination prescribed intentionally, or a system-coding error.

## Why This Denial Is Appealable

Duplicate-therapy denials are coverage determinations and are reviewable under federal appeal rights. Under ACA §2719, non-grandfathered plans must offer internal appeal and access to independent external review. Under ERISA §503, employer-plan members are entitled to full-and-fair review including the specific clinical criteria applied. Internal appeals are typically due within 180 days of the denial notice; external review requests must generally be filed within 4 months of an adverse internal determination. If delay poses a serious clinical risk, request an expedited review.

## The Concrete Appeal Process

1. Identify from the denial letter exactly which current or recent medication Cigna is treating as duplicative. 2. Establish whether this is a class switch (prior agent stopped before new one started), a clinically intentional combination, or a coding/timing error. 3. Have the prescriber draft a letter clarifying the treatment sequence or, if combination use is intended, the clinical rationale. 4. Submit the internal appeal with that letter and supporting chart documentation. 5. If denied internally, escalate to independent external review.

## Documentation to Gather

• Medication history with dates: Start and stop dates for all relevant JAK inhibitors and biologics, making the sequence explicit and showing no true duplication.
• Prescriber clarification letter: Explains whether this is a switch or a combination and, if the latter, the clinical rationale supported by the applicable specialty guideline organization.
• Diagnosis and treatment course: Chart notes documenting the condition being treated, prior therapies tried, and clinical response or failure.
• Cigna coverage policy: The specific policy cited in the denial, obtained to ensure the appeal addresses the exact criteria applied.
• FDA prescribing label: For the ordered JAK inhibitor, confirming the approved indication.

## Criteria-Mapping Structure

Obtain Cigna's published medical/coverage policy for the ordered JAK inhibitor and its definition of duplicate therapy. Address each criterion directly:

| Duplicate-Therapy Criterion | Your Evidence | |---|---| | [Copy exact criterion from Cigna policy] | [Medication dates, prescriber letter, chart note] | | [Copy exact criterion from Cigna policy] | [Medication dates, prescriber letter, chart note] |

Clarity about the medication timeline — with specific start and stop dates — is the single most important element of this appeal.